Hochuekkito Efficacy in Late-Onset Hypogonadism (LOH) Patients

受付:2012年9月30日,受理:2013年2月25日 Abstract The purpose of this study is to evaluate the efficacy of hochuekkito for late-onset hypogonadism (LOH) patients. We administered hochuekkito 7.5 g/day for 8 weeks to 47 patients with LOH whose AMS scale was more than 27. We assessed the patients’ symptom change with the AMS, SHIM, SDS, BDI, and SF-36. We measured their endocrine profiles and levels of their cytokines. At the end of study, 31 of 47 patients were evaluable. No significant difference in subjective symptoms was seen with any questionnaire after 8 weeks hochuekkito administration. However, hochuekkito significantly increased free testosterone and decreased ACTH/cortisol levels. Thus we believe hochuekkito is beneficial for the treatment of LOH.

[1]  N. Nonomura,et al.  Change in cytokine levels after administration of saikokaryuukotsuboreito or testosterone in patients with symptoms of late-onset hypogonadism , 2011, The aging male : the official journal of the International Society for the Study of the Aging Male.

[2]  T. Yanase,et al.  Late‐onset hypogonadism (LOH) and androgens: Validity of the measurement of free testosterone levels in the diagnostic criteria in Japan , 2009, International journal of urology : official journal of the Japanese Urological Association.

[3]  I. Thompson,et al.  Investigation, treatment and monitoring of late-onset hypogonadism in males , 2008, European journal of endocrinology.

[4]  F. Thomson,et al.  Innovative Approaches for the Treatment of Depression: Targeting the HPA Axis , 2008, Neurochemical Research.

[5]  K. Fujita,et al.  Comparative study on evaluation methods for serum testosterone level for PADAM diagnosis , 2005, International Journal of Impotence Research.

[6]  Pasi Pöllänen,et al.  The Aging Males' Symptoms (AMS) scale: Update and compilation of international versions , 2003, Health and quality of life outcomes.

[7]  Makoto Kawai,et al.  Cross-cultural validation of the Beck Depression Inventory-II in Japan , 2002, Psychiatry Research.

[8]  D. Klein,et al.  A pilot study of noradrenergic and HPA axis functioning in PTSD vs. panic disorder , 2002, Psychiatry Research.

[9]  B. Lunenfeld,et al.  Investigation, treatment and monitoring of late-onset hypogonadism in males. Official Recommendations of ISSAM , 2002, The aging male : the official journal of the International Society for the Study of the Aging Male.

[10]  C. Invitti,et al.  Salivary cortisol measurement in normal-weight, obese and anorexic women: comparison with plasma cortisol. , 2001, European journal of endocrinology.

[11]  I. Osterloh,et al.  The international index of erectile function (IIEF): a multidimensional scale for assessment of erectile dysfunction. , 1997, Urology.

[12]  J. E. Brazier,et al.  Validating the SF-36 health survey questionnaire: new outcome measure for primary care. , 1992, BMJ.

[13]  F. László,et al.  Evidence that the effects of arginine-8-vasopressin (AVP) on pituitary corticotropin (ACTH) release are mediated by a novel type of receptor , 1984, Peptides.

[14]  W. Vale,et al.  Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin , 1981 .

[15]  W W Zung,et al.  Self-rating depression scale in an outpatient clinic. Further validation of the SDS. , 1965, Archives of general psychiatry.

[16]  J. Kaufman,et al.  Investigation, treatment, and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA, and ASA recommendations. , 2009, European urology.

[17]  A. Schatzberg,et al.  A corticosteroid/dopamine hypothesis for psychotic depression and related states. , 1985, Journal of psychiatric research.